Remodulin
Payments companies reported to CMS as associated with Remodulin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Remodulin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Remodulin
These are the largest totals companies reported as associated with Remodulin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $61,152.35 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $47,670.55 |
| Rajan Saggar | Los Angeles, CA | Pulmonary Disease | $27,387.19 |
| Naomi Habib | Phoenix, AZ | Critical Care Medicine (Internal Medicine) | $20,712.46 |
| Harrison Farber | Boston, MA | Pulmonary Disease | $18,089.96 |
| Robert Schilz | Cleveland, OH | Critical Care Medicine (Internal Medicine) | $15,882.11 |
| Jacqueline Brewer | Sterling Heights, MI | Adult Health (Nurse Practitioner) | $14,907.80 |
| Franck Rahaghi | Weston, FL | Pulmonary Disease | $13,968.42 |
| Stephen Chan | Pittsburgh, PA | Cardiovascular Disease | $13,716.90 |
| Mardi Gomberg-Maitland | Washington, DC | Cardiovascular Disease | $13,513.82 |
Prescribed Remodulin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.